Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

With approximately 60% of prescription drugs coming from Europe, including major brands like Ozempic, Botox and Eliquis, many ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...